RxDoctor Payments Data

Manuel Padilla, DO

Family Medicine · El Paso, TXNPI 1164440400

Payments from drug & device makers

$21,460in general payments, 2019–2025

Across 1,065 payments — averaging $20.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$6K
  • AbbVie$3K
  • Lilly USA, LLC$2K
  • Abbott$1K
  • AstraZeneca$1K
  • Amgen$997
  • plus $8K from 42 others

What the payments were for

  • Food & beverage$21,429100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,460 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$63,408
Medicare patients
94
Services billed
2,723

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$169,986
MounjaroTirzepatide53$69,009
TrulicityDulaglutide31$58,287
Synjardy XrEmpagliflozin/Metformin Hcl31$50,097
FarxigaDapagliflozin Propanediol33$43,539
JardianceEmpagliflozin25$38,794
EliquisApixaban22$30,710
ProliaDenosumab16$26,789
LinzessLinaclotide14$20,382
Xigduo XrDapaglifloz Propaned/Metformin20$18,486
Tresiba Flextouch U-200Insulin Degludec14$13,200
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,926
VascepaIcosapent Ethyl12$10,026
Repatha SureclickEvolocumab11$6,079
Omega-3 Acid Ethyl Esters26$4,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$5,709$169,986110 claims
Lilly USA, LLCMounjaro, Trulicity$2,013$127,29684 claims
Boehringer IngelheimSynjardy Xr, Jardiance$917$88,89156 claims
AstraZenecaFarxiga$1,039$43,53933 claims
PfizerEliquis$537$30,71022 claims
AmgenProlia$997$26,78916 claims
AbbVieLinzess, Synthroid$2,505$22,20128 claims
GSKTrelegy Ellipta$856$11,92617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →